Peytant Solutions
ApprovedPre-clinical outcomes¹ show the AMStent System is associated with significantly less mucus accumulation, stent migration, inflammation, and granuloma formation than a commercially available control stent - outcomes that matter for patients with pulmonary obstructions.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Funding information not available
About
Pre-clinical outcomes¹ show the AMStent System is associated with significantly less mucus accumulation, stent migration, inflammation, and granuloma formation than a commercially available control stent - outcomes that matter for patients with pulmonary obstructions.
Digital HealthAI / Machine Learning